PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up

Core Insights - Pacific Biosciences of California, Inc. (PacBio) reported an adjusted loss per share of 12 cents in Q4 2025, an improvement from a loss of 20 cents per share in the previous year, exceeding the Zacks Consensus Estimate by 36.8% [1] - The company achieved total revenues of $44.6 million in Q4, reflecting a year-over-year increase of 13.8% and surpassing the Zacks Consensus Estimate by 9.4% [2] Revenue Breakdown - Revenues from the Americas reached $20.7 million, a 3% increase year over year [3] - The Asia-Pacific region generated $9.3 million in revenues, marking a 4% year-over-year growth [3] - The EMEA region saw revenues of $14.6 million, which is a significant 45% increase year over year [3] Segment Analysis - Total product revenues were $38.9 million, up 14.3% from the same quarter last year [4] - Instrument revenues accounted for $17.3 million, reflecting a 13.1% year-over-year increase, including sales of 21 Revio and 42 Vega sequencing systems [4] - Consumables revenues for Q4 were $21.6 million, up 14.9% year over year, with annualized Revio pull-through per system at $242,000 [5] Margin and Expense Trends - Adjusted gross profit increased by 44.7% year over year to $17.8 million, with adjusted gross margin expanding by 900 basis points to 41% [6] - Sales, general, and administrative expenses decreased by 18.2% year over year to $34.1 million, while research and development expenses fell by 16.7% to $22.9 million [6] - Total operating loss narrowed to $41.2 million from $153 million in the prior year [7] Financial Position and Guidance - PacBio ended Q4 2025 with cash and investments totaling $279.5 million, down from $298.7 million at the end of Q3 2025 [10] - For 2026, the company projects revenues to grow between 3% and 12% year over year, estimating total revenues of $165 million to $180 million [11] Strategic Developments - The company advanced its focus on long-read sequencing through various clinical and research initiatives, including joining the iHope initiative and collaborations with the n-Lorem Foundation and EspeRare [13] - PacBio launched CiFi, a new long-read 3C method, and completed the sale of its short-read sequencing assets for approximately $48.1 million, enhancing its financial position [14]